TW228513B - - Google Patents

Info

Publication number
TW228513B
TW228513B TW082100227A TW82100227A TW228513B TW 228513 B TW228513 B TW 228513B TW 082100227 A TW082100227 A TW 082100227A TW 82100227 A TW82100227 A TW 82100227A TW 228513 B TW228513 B TW 228513B
Authority
TW
Taiwan
Application number
TW082100227A
Other languages
Chinese (zh)
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Application granted granted Critical
Publication of TW228513B publication Critical patent/TW228513B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW082100227A 1992-01-22 1993-01-15 TW228513B (,)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/824,132 US5217996A (en) 1992-01-22 1992-01-22 Biaryl substituted 4-amino-butyric acid amides

Publications (1)

Publication Number Publication Date
TW228513B true TW228513B (,) 1994-08-21

Family

ID=25240671

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082100227A TW228513B (,) 1992-01-22 1993-01-15

Country Status (14)

Country Link
US (2) US5217996A (,)
EP (1) EP0555175A1 (,)
JP (1) JPH05310664A (,)
KR (1) KR930016393A (,)
AU (1) AU666902B2 (,)
CA (1) CA2087652A1 (,)
FI (1) FI930195A7 (,)
HU (1) HUT63376A (,)
IL (1) IL104387A0 (,)
MX (1) MX9300310A (,)
NO (1) NO930193L (,)
NZ (1) NZ245716A (,)
TW (1) TW228513B (,)
ZA (1) ZA93421B (,)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
HRP950558A2 (en) * 1994-11-15 1997-12-31 Scott M. Wilhelm Substituted 4-biarylbutric or biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
ES2132882T3 (es) * 1995-02-22 1999-08-16 Novartis Ag Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina 1.
MY132550A (en) 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
HK1039894A1 (zh) * 1999-03-29 2002-05-17 Bristol-Myers Squibb Company 使用血管肽酶抑制物治疗心绞痛
EP1467728B1 (en) * 2002-01-17 2007-08-22 Novartis AG Pharmaceutical compositions comprising valsartan and nep inhibitors
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
ATE550656T1 (de) * 2003-08-20 2012-04-15 Alere San Diego Inc Verfahren und zusammensetzungen zur messung biologisch aktiver natriuretischer peptide und zur verbesserung ihres therapeutischen potentials
EA200700243A1 (ru) * 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2459809C2 (ru) * 2005-11-09 2012-08-27 Новартис Аг Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
EP1903027A1 (en) 2006-09-13 2008-03-26 Novartis AG Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
SI2121578T1 (sl) * 2007-01-12 2016-12-30 Novartis Ag Postopek za pripravo 5-bifenil-4-amino-2-metil pentanojske kisline
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) * 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
JP2010538071A (ja) 2007-09-07 2010-12-09 セラヴァンス， インコーポレーテッド 二重作用性降圧剤
RU2518098C2 (ru) * 2007-10-05 2014-06-10 Верастэм,Инк. Пиримидинзамещенные производные пурина, фармацевтическая композиция на их основе, способ ингибирования протеинкиназ, способ лечения или профилактики заболеваний, чувствительных к ингибированию протеинкиназ и способ лечения пролиферативных заболеваний
US8212052B2 (en) * 2007-12-11 2012-07-03 Theravance, Inc. Dual-acting benzoimidazole antihypertensive agents
AU2012202949B2 (en) * 2008-01-17 2015-01-22 Novartis Ag Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
PE20091364A1 (es) * 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
JP2011518884A (ja) 2008-04-29 2011-06-30 セラヴァンス， インコーポレーテッド 二重活性抗高血圧剤
CN101607875B (zh) * 2008-06-17 2012-07-25 中国石油化学工业开发股份有限公司 制造环烷酮的方法
JP2011529072A (ja) 2008-07-24 2011-12-01 セラヴァンス， インコーポレーテッド 二重作用血圧降下薬
CN101774941A (zh) * 2009-01-13 2010-07-14 浙江九洲药业股份有限公司 2-酰基氨基-3-联苯基丙酸的制备及拆分方法
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN102448928B (zh) * 2009-05-28 2014-10-01 诺华股份有限公司 作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物
EP2594557B1 (en) * 2009-05-28 2016-08-10 Novartis AG Substituted aminopropionic derivatives as neprilysin inhibitors
JP5833000B2 (ja) 2009-07-07 2015-12-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 二重に作用するピラゾール抗高血圧症薬
EP2456762B1 (en) 2009-07-22 2013-10-16 Theravance, Inc. Dual-acting oxazole antihypertensive agents
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2526095A1 (en) 2010-01-19 2012-11-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
ES2550485T3 (es) * 2010-01-22 2015-11-10 Novartis Ag Intermedios de inhibidores de la endopeptidasa neutra y método de preparación de los mismos
KR101476937B1 (ko) * 2010-08-23 2014-12-24 노파르티스 아게 Ｎｅｐ 억제제의 제조를 위한 중간체의 제조 방법
MX2013002149A (es) 2010-08-23 2013-04-03 Novartis Ag Nuevo proceso para la preparacion de intermediarios utiles para la elaboracion de inhibidores de nep.
US20130158088A1 (en) 2010-08-24 2013-06-20 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
US8673974B2 (en) * 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
CN103261168B (zh) 2010-12-15 2015-08-05 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
AU2011343899B2 (en) 2010-12-15 2016-06-30 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
RU2604522C2 (ru) 2011-02-17 2016-12-10 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи,ЭлЭлСи Замещенные аминомасляные производные в качестве ингибиторов неприлизина
ES2564275T3 (es) 2011-02-17 2016-03-21 Theravance Biopharma R&D Ip, Llc Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CA2835220A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
JP5959074B2 (ja) 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
CN103748070B (zh) 2011-05-31 2015-06-24 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
AR089955A1 (es) * 2012-02-15 2014-10-01 Theravance Inc Proceso para preparar compuestos de acido 4-amino-5-bifenil-4-il-2-hidroximetil-2-metil-pentanoico
CN104350052B (zh) 2012-05-31 2017-05-31 施万生物制药研发Ip有限责任公司 一氧化氮供体脑啡肽酶抑制剂
SMT201700306T1 (it) 2012-06-08 2017-07-18 Theravance Biopharma R&D Ip Llc Inibitori di neprilisina
US8871792B2 (en) 2012-06-08 2014-10-28 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
SG11201500845UA (en) 2012-08-08 2015-03-30 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
US9517226B2 (en) 2012-08-24 2016-12-13 Novartis Ag Inhibitors for treating diseases characterized by atrial enlargement or remodeling
EP2956464B1 (en) 2013-02-14 2018-03-28 Novartis AG Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
KR20150119107A (ko) 2013-02-14 2015-10-23 노파르티스 아게 개선된 생체내 효능을 갖는 nep 억제제로서의 치환된 비스페닐 부탄산 유도체
EP2956141A4 (en) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc NEW USES
LT2964616T (lt) 2013-03-05 2017-07-25 Theravance Biopharma R&D Ip, Llc Neprilizino inhibitoriai
CN104230865B (zh) * 2013-06-13 2018-01-09 上海翰森生物医药科技有限公司 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
PL3626270T3 (pl) 2013-08-26 2024-04-08 Novartis Ag Leczenie chorób sercowo-naczyniowych
EP3038653A1 (en) 2013-08-26 2016-07-06 Novartis AG New use
CN105992763A (zh) 2014-01-30 2016-10-05 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
EP3099668B1 (en) 2014-01-30 2022-05-04 Theravance Biopharma R&D IP, LLC 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
WO2015154673A1 (en) * 2014-04-10 2015-10-15 Zhaoyin Wang Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases
ES2745819T3 (es) 2014-08-07 2020-03-03 Intra Cellular Therapies Inc Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
CN106458857A (zh) * 2014-08-27 2017-02-22 上海翰森生物医药科技有限公司 AHU‑377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
CN105367438A (zh) * 2014-08-27 2016-03-02 上海翰森生物医药科技有限公司 AHU-377α-苯乙胺盐多晶型及其制备方法和应用
CN105461587A (zh) * 2014-08-27 2016-04-06 上海翰森生物医药科技有限公司 Ahu-377半钙盐晶型及其制备方法和应用
CN105622452A (zh) * 2014-08-27 2016-06-01 上海翰森生物医药科技有限公司 Ahu-377结晶型游离酸及其制备方法和应用
WO2016037098A1 (en) 2014-09-04 2016-03-10 Concert Pharmaceuticals, Inc. Deuterated sacubitril
HUE046278T2 (hu) 2014-11-14 2020-02-28 Zentiva Ks Módszer AHU-377 gyógyszerészetben alkalmazható formáinak elõállítására, izolálására és tisztítására
CN105693543B (zh) * 2014-12-15 2018-08-10 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
CN104557600B (zh) * 2015-01-26 2016-05-04 苏州明锐医药科技有限公司 沙库比曲的制备方法
KR102640906B1 (ko) 2015-02-11 2024-02-27 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 네프릴리신 저해제로서 (2s,4r)-5-(5''-클로로-2''-플루오로비페닐-4-일)-4-(에톡시옥살릴아미노)-2-히드록시메틸-2-메틸펜타노익산
TW201632493A (zh) 2015-02-13 2016-09-16 諾華公司 新穎方法
HRP20210040T1 (hr) 2015-02-19 2021-04-02 Theravance Biopharma R&D Ip, Llc (2r,4r)-5-(5′-klor-2’-fluorbifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentanska kiselina
WO2016135751A1 (en) 2015-02-25 2016-09-01 Mylan Laboratories Limited Novel process for the preparation of sacubitril and its intermediates
CN105963296B (zh) * 2015-03-12 2020-01-21 深圳信立泰药业股份有限公司 一种含有阿利沙坦酯或其盐或其水解产物或其水解产物盐的药物组合物及其用途
US10233144B2 (en) * 2015-03-20 2019-03-19 Crystal Pharmatech Co., Ltd. Crystalline form of AHU377, preparation method and use thereof
HRP20230480T1 (hr) 2015-05-11 2023-07-21 Novartis Ag Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca
EP3302460A1 (en) 2015-05-29 2018-04-11 Novartis AG Sacubitril and valsartan for treating metabolic disease
CN104860894B (zh) * 2015-06-10 2017-05-17 北京博全健医药科技有限公司 一种抗心衰药lcz696的制备方法
KR20200117037A (ko) * 2015-06-12 2020-10-13 테바 파마슈티컬스 인터내셔널 게엠베하 삼나트륨 발사르탄:사쿠비트릴의 고체 형태
WO2016203500A2 (en) 2015-06-19 2016-12-22 Actavis Group Ptc Ehf. Preparation of sacubitril or salt thereof and novel intermediates in the preparation of sacubitril
US11786498B2 (en) 2015-07-02 2023-10-17 Novartis Ag Sacubitril calcium salts
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
WO2017009784A1 (en) 2015-07-14 2017-01-19 Cadila Healthcare Limited Solid state forms of trisodium salt of valsartan/sacubitril complex and sacubitril
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
FI3325013T4 (fi) 2015-07-23 2023-10-11 Liukoisen guanylaattisyklaasin (sgc) stimulaattoreita ja/tai aktivaattoreita yhdistelmänä neutraalin endopeptidaasin estäjän (nep-estäjä) ja/tai angiotensiini aii -antagonistin kanssa ja niiden käyttö
WO2017029261A1 (de) * 2015-08-19 2017-02-23 Bayer Pharma Aktiengesellschaft Kombinationspräparat umfassend finerenone und einen nep-inhibitor (sacubitril)
WO2017033128A1 (en) 2015-08-25 2017-03-02 Novartis Ag Biphenyl-substitued 4-amino-butyric acid derivatives and their use in the synthesis of nep inhibitors
US10596151B2 (en) 2015-08-28 2020-03-24 Novartis Ag Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme
WO2017051326A1 (en) 2015-09-23 2017-03-30 Novartis Ag New processes and intermediates useful in synthesis of nep inhibitors
US20180311241A1 (en) 2015-10-29 2018-11-01 Cadila Healthcare Limited Pharmaceutical synergistic combination
HK1254367A1 (zh) 2015-12-10 2019-07-19 Novartis Ag 新的工艺和中间体
BR112018011788A2 (pt) * 2015-12-11 2018-12-04 Zentiva Ks formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
CN106977417A (zh) * 2016-01-15 2017-07-25 常州方楠医药技术有限公司 一种沙库比曲钠盐的晶型及其制备方法
PT3411021T (pt) 2016-02-03 2025-08-06 Novartis Ag Nova utilização de uma combinação de sacubitril e valsartan
PL3408260T3 (pl) 2016-03-08 2021-11-08 Theravance Biopharma R&D Ip, Llc Krystaliczny kwas (2S,4R)-5-(5'-chloro-2-fluoro-[1,1'-bifenyl]-4-ilo)-2-(etoksymetylo)-4- (3-hydroksyizoksazolo-5-karboksyamido)-2-metylopentanowy i jego zastosowania
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
CN105753733B (zh) * 2016-04-15 2019-06-18 苏州晶云药物科技股份有限公司 Ahu377的晶型及其制备方法与用途
CN105820064A (zh) * 2016-04-18 2016-08-03 浙江天宇药业股份有限公司 一种联苯基丙氨醇衍生物的合成方法及中间体
WO2017191620A1 (en) * 2016-05-06 2017-11-09 Sun Pharmaceutical Industries Limited A crystalline form of a salt of sacubitril and a process of its preparation
WO2018007919A1 (en) 2016-07-05 2018-01-11 Novartis Ag New process for early sacubitril intermediates
CN107602399B (zh) * 2016-07-11 2020-09-25 江西东邦药业有限公司 一种脑啡肽酶抑制剂中间体的制备方法
CN109563019A (zh) * 2016-08-17 2019-04-02 诺华股份有限公司 Nep抑制剂合成的新方法和中间体
CN106318988B (zh) * 2016-08-23 2020-11-03 迪嘉药业集团有限公司 一种lcz696关键中间体的制备方法
WO2018045505A1 (zh) 2016-09-07 2018-03-15 诺瑞特国际药业股份有限公司 沙库比曲钠盐新晶型
CN106478437A (zh) * 2016-09-27 2017-03-08 南通常佑药业科技有限公司 一种γ‑氨基戊酸酯衍生物的制备方法
CN106496055A (zh) * 2016-10-09 2017-03-15 杭州科巢生物科技有限公司 一种抗心衰新药的关键组分沙库比曲的新合成方法
US10857132B2 (en) 2016-10-10 2020-12-08 Laurus Labs Limited Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
RU2019115782A (ru) 2016-10-28 2020-11-30 Биокон Лимитед Аморфный тринатрий сакубитрил вальсартан и способ его получения
ES2883363T3 (es) 2016-12-23 2021-12-07 Novartis Ag Proceso nuevo para intermedios iniciales de sacubitrilo
WO2018153895A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
CN106831473B (zh) * 2017-02-22 2019-07-16 江西瑞雅药业有限公司 3-酰胺基-4-(2’-烷氧基-4-联苯基)丁酸衍生物及其制备方法、药物组合物
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
MX391562B (es) 2017-07-28 2025-03-21 Synthon Bv Composicion farmaceutica que comprende sacubitril y valsartan
WO2019073062A1 (en) 2017-10-13 2019-04-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) TABLET CONTAINING VALSARTAN AND SACUBITRIL
CN108530371B (zh) * 2017-12-27 2020-09-01 浙江天宇药业股份有限公司 一种沙库比曲钠盐、沙库比曲游离酸与乙酸的共晶物、其晶型、晶型的制备方法及用途
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
UY38072A (es) * 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
GB201810326D0 (en) * 2018-06-22 2018-08-08 Johnson Matthey Plc Crystalline form of sacubitril, its preparation and use
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN109503404A (zh) * 2018-12-28 2019-03-22 凯瑞斯德生化(苏州)有限公司 一种lcz-696关键中间体的制备方法
CN110128298B (zh) * 2019-06-13 2021-08-03 南京一心和医药科技有限公司 一种沙库巴曲中间体的合成方法
CN113135836A (zh) * 2020-01-20 2021-07-20 鲁南制药集团股份有限公司 一种沙库巴曲钙盐的制备方法
CN111253425B (zh) * 2020-02-21 2022-04-29 常州南京大学高新技术研究院 一种1,3-双[2-(3,4-环氧环己基)乙基]四甲基二硅氧烷的合成方法
JP7064527B2 (ja) * 2020-05-01 2022-05-10 ノバルティス アーゲー サクビトリルカルシウム塩
KR20220012821A (ko) 2020-07-23 2022-02-04 주식회사 종근당 이중 작용 복합 화합물의 결정형 및 이의 제조방법
CN112661671B (zh) * 2020-12-22 2022-04-22 江苏阿尔法药业股份有限公司 一种沙库巴曲中间体的制备方法
WO2022224274A1 (en) 2021-04-20 2022-10-27 Mylan Laboratories Limited Polymorphic forms of sacubitril-telmisartan (1:1)
CN117645555A (zh) * 2023-11-30 2024-03-05 南京欧信医药技术有限公司 一种利用连续流管式反应器合成沙库巴曲中间体的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE250531C (,) *
US2543267A (en) * 1950-01-04 1951-02-27 Parke Davis & Co Hydroxyethyl-acylamidobiphenylyl ketones
US4206232A (en) * 1976-05-10 1980-06-03 E. R. Squibb & Sons, Inc. Relieving hypertension with carboxyalkylacylamino acids
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4721726A (en) * 1980-12-18 1988-01-26 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
US4939261A (en) * 1984-06-08 1990-07-03 Ciba-Geigy Corporation N-substituted butyramide derivatives useful for treatment of conditions responsive to inhibition of enkephalinase
US5096925A (en) * 1984-06-08 1992-03-17 Ciba-Geigy Corporation N-substituted butyramide derivatives
EP0225292A3 (en) * 1985-12-06 1988-11-30 Ciba-Geigy Ag Certain n-substituted butyramide derivatives
DD250531A1 (de) * 1985-12-23 1987-10-14 Adw Ddr Verfahren zur herstellung von malonylaminosaeure-p-nitrobenzylestern
CA1337400C (en) * 1987-06-08 1995-10-24 Norma G. Delaney Inhibitors of neutral endopeptidase
US5169976A (en) * 1987-11-25 1992-12-08 Pfizer Inc. N-(biphenylmethyl)-3-hydroxyglutaramic acid and derivatives as hypocholesterolemic agents
WO1991005555A2 (en) * 1989-10-13 1991-05-02 The Salk Institute Biotechnology/Industrial Associates, Inc. N-acyl peptide metalloendopeptidase inhibitors and methods of using same
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides

Also Published As

Publication number Publication date
US5217996A (en) 1993-06-08
JPH05310664A (ja) 1993-11-22
NO930193D0 (no) 1993-01-21
AU666902B2 (en) 1996-02-29
HU9300166D0 (en) 1993-04-28
EP0555175A1 (en) 1993-08-11
CA2087652A1 (en) 1993-07-23
FI930195A7 (fi) 1993-07-23
IL104387A0 (en) 1993-05-13
FI930195A0 (fi) 1993-01-18
US5354892A (en) 1994-10-11
NZ245716A (en) 1995-07-26
MX9300310A (es) 1993-07-01
HUT63376A (en) 1993-08-30
ZA93421B (en) 1993-07-22
AU3184293A (en) 1993-07-29
KR930016393A (ko) 1993-08-26
NO930193L (no) 1993-07-23

Similar Documents

Publication Publication Date Title
TW228513B (,)
TW221382B (,)
NO933836L (,)
TW229263B (,)
EP0726756A4 (,)
TW240286B (,)
DK0576346T3 (,)
DK0632741T3 (,)
DK0554977T3 (,)
DK0553681T3 (,)
NO175048C (,)
DK0625187T3 (,)
TW223174B (,)
DK0574276T3 (,)
DK0564197T3 (,)
TW240175B (,)
TW222323B (,)
DK0596569T3 (,)
NO924356L (,)
DK0571172T3 (,)
DK0576097T3 (,)
TW252922B (,)
TW223140B (,)
DK0590732T3 (,)
FR2690133B1 (,)